Next Science Dividends and Buybacks

Dividend criteria checks 0/6

Next Science does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-64.0%

Buyback Yield

Total Shareholder Yield	-64.0%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Oct 22

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Jul 26

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

Jun 08

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Apr 16

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Mar 06

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Dec 26

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Oct 26

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

May 13

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Feb 03

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Jan 25

What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 23

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXS's dividend payments have been increasing.

Dividend Yield vs Market

Next Science Dividend Yield vs Market

How does NXS dividend yield compare to the market?
Segment	Dividend Yield
Company (NXS)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.2%
Industry Average (Medical Equipment)	1.6%
Analyst forecast (NXS) (up to 3 years)	0%

Notable Dividend: Unable to evaluate NXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NXS's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NXS has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 11:12
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Next Science Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elyse Shapiro	Bell Potter
Martyn Jacobs	Canaccord Genuity
Dr Benson	Wilsons Advisory and Stockbroking Ltd.

Next Science Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024

Consensus EPS estimates fall by 11%

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024

Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

New minor risk - Share price stability

Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Next Science Limited, Annual General Meeting, May 03, 2024

Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022)

Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Consensus revenue estimates decrease by 10%

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Consensus revenue estimates increase by 26%, EPS downgraded

New minor risk - Shareholder dilution

First half 2023 earnings released: US$0.04 loss per share (vs US$0.032 loss in 1H 2022)

New minor risk - Financial data availability

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

New minor risk - Share price stability

Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products

Next Science Limited Announces Executive Changes

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

Founder & CTO recently sold AU$1.5m worth of stock

Consensus EPS estimates fall from profit to US$0.051 loss, revenue upgraded

Full year 2022 earnings released: US$0.06 loss per share (vs US$0.047 loss in FY 2021)

Next Science Limited, Annual General Meeting, May 26, 2023

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Forecast breakeven date pushed back to 2024

Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited

Insufficient new directors

Next Science Limited Announces the Launch of Topical Collagen Products

Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE

First half 2022 earnings released: US$0.032 loss per share (vs US$0.021 loss in 1H 2021)

Forecast breakeven date pushed back to 2024

Next Science Limited to Report First Half, 2022 Results on Aug 25, 2022

Consensus forecasts updated

Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer

Insufficient new directors

MD, CEO & Executive Director recently sold AU$123k worth of stock

Next Science Limited, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Insufficient new directors

Founder & CTO recently sold AU$8.6m worth of stock

First half 2021 earnings released: US$0.021 loss per share (vs US$0.037 loss in 1H 2020)

Next Science Limited Agrees to Open Negotiations with Zimmer, Inc

Next Science Limited Provides Revenue Guidance for the First Half of 2021

Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration for Sale in Australia

Independent Non-Executive Chairman George Savvides has left the company

Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Independent Non-Executive Director recently sold AU$564k worth of stock

MD, CEO & Executive Director exercised options to buy AU$2.5m worth of stock.

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future

Next Science Limited, Annual General Meeting, May 05, 2021

Analysts update estimates

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day high: AU$1.38

Here's Why We're Watching Next Science's (ASX:NXS) Cash Burn Situation

Next Science Limited to Report Fiscal Year 2020 Results on Feb 22, 2021

Did Next Science Limited (ASX:NXS) Insiders Buy Up More Shares?

Next Science Limited Receives CE Mark Approval for BlastX

Do Institutions Own Next Science Limited (ASX:NXS) Shares?

New 90-day high: AU$1.37

Non-Executive Director recently bought AU$149k worth of stock